{"id":534530,"date":"2021-09-07T04:33:06","date_gmt":"2021-09-07T08:33:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/"},"modified":"2021-09-07T04:33:06","modified_gmt":"2021-09-07T08:33:06","slug":"hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/","title":{"rendered":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference"},"content":{"rendered":"
\n

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED<\/a>\u201d) (Nasdaq\/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3K\u03b4 inhibitor HMPL-689), savolitinib (ORPATHYS\u00ae<\/sup> in China) and fruquintinib (ELUNATE\u00ae<\/sup> in China) will be presented at the upcoming 2021 European Society for Medical Oncology (\u201cESMO\u201d) Virtual Congress taking place on September 16-21, 2021.<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n AMDIZALISIB (also known as HMPL-689)<\/strong>
\n
\n
\n <\/strong>\n <\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\n\n A phase\u202fIb study result of HMPL-689, a PI3K\u03b4 inhibitor, in Chinese patients with relapsed\/refractory lymphoma<\/strong>\n <\/td>\n<\/tr>\n
\n Lead Author:<\/strong>\n <\/td>\nJunning Cao, MD, Fudan University Shanghai Cancer Center<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nProffered Paper \u2013 Haematological Malignancies<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n\n 833O<\/a>\n <\/td>\n<\/tr>\n
\n Date & Time:<\/strong>\n <\/td>\nMonday, September 20, 2021 2:10 pm CEST<\/td>\n<\/tr>\n
\n Location:<\/strong>\n <\/td>\nChannel 3<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n SAVOLITINIB<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\n\n ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib<\/strong>\n <\/td>\n<\/tr>\n
\n Lead Author:<\/strong>\n <\/td>\nHelena Yu, MD, Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nePoster<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n\n 1239P<\/a>\n <\/td>\n<\/tr>\n
\n Date available:<\/strong>\n <\/td>\nMonday, September 13, 2021<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n FRUQUINTINIB<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Title:<\/strong>\n <\/td>\n\n An open-label, phase Ib\/II study to evaluate the safety and efficacy of fruquintinib in combination with tislelizumab in patients with advanced triple negative breast cancer<\/strong>\n <\/td>\n<\/tr>\n
\n Lead Author:<\/strong>\n <\/td>\nDebu Tripathy, MD, The University of Texas MD Anderson Cancer Center<\/td>\n<\/tr>\n
\n Session:<\/strong>\n <\/td>\nePoster<\/td>\n<\/tr>\n
\n Presentation Number:<\/strong>\n <\/td>\n\n 337TiP<\/a>\n <\/td>\n<\/tr>\n
\n Date available:<\/strong>\n <\/td>\nMonday, September 13, 2021<\/td>\n<\/tr>\n<\/table>\n

\n About Amdizalisib<\/strong>\n <\/p>\n

Amdizalisib (HMPL-689) is a novel, selective and potent oral inhibitor targeting the isoform PI3K\u03b4. Amdizalisib\u2019s pharmacokinetics (\u201cPK\u201d) properties are favorable with good oral absorption, moderate tissue distribution and low clearance in preclinical PK studies, suggesting a low risk of drug accumulation and drug-to-drug interaction. Because of its high target selectivity and optimal PK profile, amdizalisib has the potential to demonstrate an optimal benefit-risk profile in this class.<\/p>\n

HUTCHMED has initiated an extensive, globally-focused clinical development pathway for amdizalisib. In addition to the currently Phase II trial and the supportive Phase I trial in China, amdizalisib is also being evaluated in an ongoing Phase I\/Ib study in the U.S. and Europe in patients with relapsed or refractory non-Hodgkin\u2019s lymphoma (NHL).<\/p>\n

HUTCHMED currently retains all rights to amdizalisib worldwide.<\/p>\n

\n About Savolitinib (ORPATHYS<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n in China)<\/strong>\n <\/p>\n

Savolitinib is an oral, potent, and highly selective mesenchymal epithelial transition receptor (MET) tyrosine kinase inhibitor (TKI) that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway that occurs because of mutations (such as exon 14 skipping alterations or other point mutations) or gene amplification.<\/p>\n

Savolitinib is marketed<\/a> in China under the brand name ORPATHYS\u00ae<\/sup> for the treatment of patients with non-small cell lung cancer (NSCLC) with MET exon 14 skipping alterations who have progressed following prior systemic therapy or are unable to receive chemotherapy. It is currently under clinical development for multiple tumor types, including lung, kidney, and gastric cancers, as a single treatment and in combination with other medicines.<\/p>\n

In 2011, following its discovery and initial development by HUTCHMED, AstraZeneca and HUTCHMED entered a global licensing agreement to jointly develop and commercialize savolitinib. Joint development in China is led by HUTCHMED, while AstraZeneca leads development outside of China. HUTCHMED is responsible for the marketing authorization, manufacturing and supply of savolitinib in China. AstraZeneca is responsible for the commercialization of savolitinib in China and worldwide. Sales of savolitinib will be recognized by AstraZeneca.<\/p>\n

\n About Fruquintinib (ELUNATE<\/strong>
\n
\n \u00ae<\/strong>
\n <\/sup>
\n in China)<\/strong>\n <\/p>\n

Fruquintinib is a highly selective and potent oral inhibitor of VEGFRs -1, -2 and -3. VEGFR inhibitors play a pivotal role in blocking tumor angiogenesis. Fruquintinib was designed to improve kinase selectivity to minimize off-target toxicities, improve tolerability and provide more consistent target coverage. The generally good tolerability in patients to date, along with fruquintinib\u2019s low potential for drug-drug interaction based on preclinical assessment, suggests that it may also be highly suitable for combinations with other anti-cancer therapies.<\/p>\n

HUTCHMED retains all rights to fruquintinib outside of China. In China, HUTCHMED is partnered with Eli Lilly and Company and is responsible for development and execution of all on-the-ground medical detailing, promotion and local and regional marketing.<\/p>\n

\n About HUTCHMED<\/strong>\n <\/p>\n

HUTCHMED (Nasdaq\/AIM: HCM; HKEX:13) is an innovative, commercial-stage, biopharmaceutical company. It is committed to the discovery and global development and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. A dedicated organization of over 1,400 personnel has advanced eleven cancer drug candidates from in-house discovery into clinical studies around the world, with its first three oncology drugs now approved and marketed. For more information, please visit: www.hutch-med.com<\/a> or follow us on LinkedIn<\/a>.<\/p>\n

\n
\n Forward-Looking Statements <\/em>
\n <\/strong>\n <\/p>\n

\n This press release contains forward-looking statements within the meaning of the \u201csafe harbor\u201d provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by words like \u201cwill,\u201d \u201cexpects,\u201d \u201canticipates,\u201d \u201cfuture,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cestimates,\u201d \u201cpipeline,\u201d \u201ccould,\u201d \u201cpotential,\u201d \u201cfirst-in-class,\u201d \u201cdesigned to,\u201d \u201cobjective,\u201d \u201cguidance,\u201d \u201cpursue,\u201d or similar terms, or by express or implied discussions regarding potential drug candidates, potential indications for drug candidates or by discussions of strategy, plans, expectations or intentions. You should not place undue reliance on these statements. Such forward-looking statements are based on the current beliefs and expectations of management regarding future events, and are subject to significant known and unknown risks and uncertainties. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those set forth in the forward-looking statements. There can be no guarantee that any of our drug candidates will be approved for sale in any market, or that any approvals which are obtained will be obtained at any particular time, or that any such drug candidates will achieve any particular revenue or net income levels. In particular, management\u2019s expectations could be affected by, among other things: unexpected regulatory actions or delays or government regulation generally; the uncertainties inherent in research and development, including the inability to meet our key study assumptions regarding enrollment rates, timing and availability of subjects meeting a study\u2019s inclusion and exclusion criteria and funding requirements, changes to clinical protocols, unexpected adverse events or safety, quality or manufacturing issues; the inability of a drug candidate to meet the primary or secondary endpoint of a study; the inability of a drug candidate to obtain regulatory approval in different jurisdictions or gain commercial acceptance after obtaining regulatory approval; global trends toward health care cost containment, including ongoing pricing pressures; uncertainties regarding actual or potential legal proceedings, including, among others, actual or potential product liability litigation, litigation and investigations regarding sales and marketing practices, intellectual property disputes, and government investigations generally; the impact of the COVID-19 pandemic or other health crises in China or globally on general economic, regulatory and political conditions; and general economic and industry conditions, including uncertainties regarding the effects of the persistently weak economic and financial environment in many countries and uncertainties regarding future global exchange rates. For further discussion of these and other risks, see HUTCHMED\u2019s filings with the U.S. Securities and Exchange Commission, The Stock Exchange of Hong Kong Limited and on AIM. HUTCHMED is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements as a result of new information, future events or otherwise.<\/em>
\n \u00a0\u00a0<\/em>\n <\/p>\n

\n CONTACTS<\/strong>\n <\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n
\n Investor Enquiries<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Mark Lee, Senior Vice President<\/td>\n+852\u00a02121\u00a08200<\/td>\n<\/tr>\n
Annie Cheng, Vice President<\/td>\n+1\u00a0(973)\u00a0567\u00a03786<\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Media Enquiries<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Americas<\/strong> \u2013 Brad Miles,
Solebury Trout<\/td>\n		+1\u00a0(917)\u00a0570\u00a07340\u00a0(Mobile)
bmiles@troutgroup.com<\/u><\/a><\/td>\n<\/tr>\n
\n Europe <\/strong>\u2013 Ben Atwell \/ Alex Shaw,
FTI Consulting<\/td>\n		+44\u00a020\u00a03727\u00a01030 \/ +44\u00a07771\u00a0913\u00a0902\u00a0(Mobile) \/ +44\u00a07779\u00a0545\u00a0055\u00a0(Mobile)
HUTCHMED@fticonsulting.com<\/a><\/td>\n<\/tr>\n
\n Asia <\/strong>\u2013 Zhou Yi,
Brunswick<\/td>\n		+852\u00a09783\u00a06894\u00a0(Mobile)
HUTCHMED@brunswickgroup.com<\/a><\/td>\n<\/tr>\n
\u00a0<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n Nominated Advisor<\/strong>\n <\/td>\n\u00a0<\/td>\n<\/tr>\n
Atholl Tweedie \/ Freddy Crossley,
Panmure Gordon (UK)\u00a0Limited<\/td>\n		+44\u00a0(20)\u00a07886\u00a02500<\/td>\n<\/tr>\n<\/table>\n

\u00a0<\/p>\n


\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3K\u03b4 inhibitor HMPL-689), savolitinib (ORPATHYS\u00ae in China) and fruquintinib (ELUNATE\u00ae in China) will be presented at the upcoming 2021 European Society for Medical Oncology (\u201cESMO\u201d) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known as HMPL-689) Title: A phase\u202fIb study result of HMPL-689, a PI3K\u03b4 inhibitor, in Chinese patients with relapsed\/refractory lymphoma Lead Author: Junning Cao, MD, Fudan University Shanghai Cancer Center Session: Proffered Paper \u2013 Haematological Malignancies Presentation Number: 833O Date & Time: Monday, September 20, 2021 2:10 pm CEST Location: Channel … <\/p>\n

Continue reading “HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-534530","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nHUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3K\u03b4 inhibitor HMPL-689), savolitinib (ORPATHYS\u00ae in China) and fruquintinib (ELUNATE\u00ae in China) will be presented at the upcoming 2021 European Society for Medical Oncology (\u201cESMO\u201d) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known as HMPL-689) Title: A phase\u202fIb study result of HMPL-689, a PI3K\u03b4 inhibitor, in Chinese patients with relapsed\/refractory lymphoma Lead Author: Junning Cao, MD, Fudan University Shanghai Cancer Center Session: Proffered Paper \u2013 Haematological Malignancies Presentation Number: 833O Date & Time: Monday, September 20, 2021 2:10 pm CEST Location: Channel … Continue reading "HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-09-07T08:33:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference\",\"datePublished\":\"2021-09-07T08:33:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/\"},\"wordCount\":1273,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/\",\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=\",\"datePublished\":\"2021-09-07T08:33:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/","og_locale":"en_US","og_type":"article","og_title":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk","og_description":"HONG KONG, SHANGHAI, China and FLORHAM PARK, N.J., Sept. 07, 2021 (GLOBE NEWSWIRE) — HUTCHMED (China) Limited (\u201cHUTCHMED\u201d) (Nasdaq\/AIM: HCM, HKEX: 13) today announces that new analyses and updates on the ongoing studies of amdizalisib (PI3K\u03b4 inhibitor HMPL-689), savolitinib (ORPATHYS\u00ae in China) and fruquintinib (ELUNATE\u00ae in China) will be presented at the upcoming 2021 European Society for Medical Oncology (\u201cESMO\u201d) Virtual Congress taking place on September 16-21, 2021. AMDIZALISIB (also known as HMPL-689) Title: A phase\u202fIb study result of HMPL-689, a PI3K\u03b4 inhibitor, in Chinese patients with relapsed\/refractory lymphoma Lead Author: Junning Cao, MD, Fudan University Shanghai Cancer Center Session: Proffered Paper \u2013 Haematological Malignancies Presentation Number: 833O Date & Time: Monday, September 20, 2021 2:10 pm CEST Location: Channel … Continue reading \"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-09-07T08:33:06+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference","datePublished":"2021-09-07T08:33:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/"},"wordCount":1273,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/","name":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=","datePublished":"2021-09-07T08:33:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMyMTA3NCM0MzkxNjcyIzIwOTY3MTU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/hutchmed-highlights-clinical-data-to-be-presented-at-the-upcoming-2021-esmo-virtual-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"HUTCHMED Highlights Clinical Data to be Presented at the Upcoming 2021 ESMO Virtual Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534530","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=534530"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/534530\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=534530"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=534530"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=534530"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}